Please assess the completion status of the following clinical trial:

Trial Title: A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CD4 cell count greater than 50 cells/mm\^3~* HIV-1 RNA viral load greater than or equal to 5000 copies/mL~* Patients must be HIV treatment experienced~* Patients diagnosed with HIV-1 infection~Exclusion Criteria:~* Female patients must not be able to have children or must be under effective contraceptives~* Female patients who are pregnant~* Have taken enfuvirtide and/or T-1249 before~* Have serious kidney problems~* Alcohol and/or drug abuse~* Have had an organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).